Author(s): Neha Rani, Tirthankar Deb, Ankita Beniwal, Astha Singh

Email(s): tirthdeb@gmail.com

DOI: 10.52711/0974-360X.2022.00876   

Address: Neha Rani, Tirthankar Deb*, Ankita Beniwal, Astha Singh
Department of Pharmacology, Kalpana Chawla Government Medical College and Hospital, Karnal, Haryana.
*Corresponding Author

Published In:   Volume - 15,      Issue - 11,     Year - 2022


ABSTRACT:
Background: WHO has declared Coronavirus 2019 (COVID-19) as pandemic on 11th March 2020. Hydroxychloroquine (HCQ) chemoprophylaxis has been approved by the Indian Council of Medical Research (ICMR) for asymptomatic healthcare workers treating suspected or confirmed COVID-19 cases and asymptomatic household contacts of confirmed patients. However, there is a scarcity of data regarding the efficacy and safety of HCQ for COVID-19 prophylaxis and treatment. Objective: The present study was designed to evaluate the adverse drug reaction (ADR) profile of HCQ prophylaxis among healthcare workers in a tertiary care teaching hospital in India. Methods: A Descriptive cross-sectional study was conducted in Kalpana Chawla Medical College and Hospital, Karnal for duration of 3 months (April-June 2020). The study was performed on the reported ADRs due to HCQ prophylaxis by the healthcare workers to the ADR monitoring centre of the institute during this period. Results: Gastrointestinal disturbance such as loose stool (16.4%) and hyperacidity (14.9%) were the most commonly reported ADRs during the study period. The incident rate of adverse drug reactions was 23.7%. The number of ADRs was found to be significantly (p<0.01) more in female as compared to male. We have observed that most of the reactions were reported following the 1st day loading dose. Conclusions: Our results showed that gastrointestinal system was most commonly affected. Loose stool and hyperacidity were most frequently reported ADRs due to HCQ prophylaxis. Larger studies are required to ensure the safety of the use of HCQ as prophylaxis for COVID 19.


Cite this article:
Neha Rani, Tirthankar Deb, Ankita Beniwal, Astha Singh. ADR profile among healthcare workers on Hydroxychloroquine prophylaxis in a tertiary care teaching hospital in India. Research Journal of Pharmacy and Technology. 2022; 15(11):5202-5. doi: 10.52711/0974-360X.2022.00876

Cite(Electronic):
Neha Rani, Tirthankar Deb, Ankita Beniwal, Astha Singh. ADR profile among healthcare workers on Hydroxychloroquine prophylaxis in a tertiary care teaching hospital in India. Research Journal of Pharmacy and Technology. 2022; 15(11):5202-5. doi: 10.52711/0974-360X.2022.00876   Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-11-61


REFERENCES:
1.    Mahase E. Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and in action. British Medical Journal (Clinical Research Edition). 2020;368:m1036. https://doi.org/10.1136/bmj.m1036
2.    WHO Coronavirus Disease (COVID-19) Dashboard. Geneva: World Health Organization; 2020 Available from: https://covid19.who.int/.
3.    Manisha Rokade, Pradnya Khandagale. Coronavirus Disease: A Review of a New Threat to Public Health. Asian Journal of Pharmaceutical Research. 2020;10(3):241-244. http://dx.doi.org/10.5958/2231-5691.2020.00042.8
4.    Kumar R, Chawla A, Gaganpreet D. A Valuable insight to the novel deadly COVID-19: A Review. Research Journal of Pharmacology and Pharmacodynamics. 2020;12(3):111-116. http://dx.doi.org/10.5958/2321-5836.2020.00021.
5.    Kishor RS, Ramhari BM. Introduction to Covid-19. Research Journal of Science and Technology. 2020; 12(4):338-345. https://doi.org/10.5958/2349-2988.2020.00051.0
6.    Ahmad S, Shoaib A, Ali S, Alam S, Alam N, Ali M, Mujtaba A, et al. Epidemiology, Risk, Myths, Pharmacotherapeutic Management and Socio- economic Burden due to Novel COVID-19: A Recent Update. Research Journal of Pharmacy and Technology. 2021; 14(4):2308-5. https://doi.org/10.52711/0974-360X.2021.00408
7.    Ghogare RD, Navale AS, Shaikh SB. Novel Corona Virus: One Biological Disaster of 2020. Research journal of Science and technology. 2020;12(2):147-156. http://dx.doi.org/10.5958/2349-2988.2020.00019.4
8.    Mor S, Saini P, Wangnoo SK, Bawa T. Worldwide spread of COVID-19 Pandemic and risk factors among Co-morbid conditions especially Diabetes Mellitus in India. Research Journal of Pharmacy and Technology. 2020;13(5):2530-2532. https://doi.org/10.5958/0974-360X.2020.00450.3
9.    Jain RS, Jain TG, Ishikar SK. Impact of Covid-19 on Changing Habits and Health Issues of the Public. Asian Journal of Management. 2020;11(4):524-528. https://www.doi.org/10.5958/2321-5763.2020.00077.3
10.    Patil PA, Jain RS. Theoretical Study and treatment of Novel COVID-19. Research Journal of Pharmacology and Pharmacodynamics. 2020;12(2):71-72. https://doi.org/10.5958/2321-5836.2020.00014.2
11.    Sharma A, Mohanan K. Obstacles Faced by Nurses working in Covid-19 Unit: A Developing Country view Point. Asian Journal of Nursing Education and Research. 2020; 10(4):459-462. https://doi.org/10.5958/2349-2996.2020.00098.1
12.    Fernandes M, Thakur JR, Gavanje MS. A Study to assess knowledge regarding covid-19 among Nursing students. Asian Journal of Nursing Education and Research. 2021; 11(1):65-67. https://www.doi.org/10.5958/2349-2996.2021.00017.3
13.    Rai P, Roy D. Death and Scarcity of Life Saving PPEs: Where is the Life of Heroes?. Asian Journal of Nursing Education and Research. 2021; 11(1):157-160. https://doi.org/10.5958/2349-2996.2021.00040.9
14.    Cohen MS. Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence. The New England journal of medicine. 2020;383:585-586. https://doi.org/10.1056/NEJMe2020388
15.    Nina PB, Dash AP. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say? Indian journal of public health. 2020;64:S125‐S127. https://doi.org/10.4103/ijph.IJPH_496_20
16.    Sinha N, Balayla G. Hydroxychloroquine and COVID-19. Postgraduate medical journal. 2020;96(1139):550-555. https://doi.org/10.1136/postgradmedj-2020-137785
17.    Revised advisory on the use of Hydroxychloroquine (HCQ) as prophylaxis for COVID-19 infection dated 22.05.2020 (in supersession of previous advisory dated 23rd March, 2020). https://www.mohfw.gov.in/pdf/RevisedadvisoryontheuseofhydroxychloroquineasprophylaxisforSARSCOVID19infection.pdf
18.    Principi N, Esposito S. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. The Lancet. Infectious diseases. 2020;20:1118. https://doi.org/10.1016/S1473-3099(20)30296-6
19.    Shah S, Das S, Jain A, Misra DP, Negi VS. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). International journal of rheumatic diseases. 2020;23:613‐619. https://doi.org/10.1111/1756-185X.13842
20.    de Barros CM, Almeida CAF, Pereira B, Costa KCM, Pinheiro FA, Maia LDB, Trindade CM, et al. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine. Pain Physician. 2020;23(4S):S351-S366.https://www.painphysicianjournal.com/linkout?issn=&vol=23&page=S351
21.    Montastruc J, Rousseau V, Durrieu G, Bagheri H. Serious adverse drug reactions with hydroxychloroquine: a pharmacovigilance study in Vigibase. Montastruc, J. L., Rousseau, V., Durrieu, G., & Bagheri, H. (2020). Serious adverse drug reactions with hydroxychloroquine: a pharmacovigilance study in Vigibase®. European journal of clinical pharmacology 76(10), 1479–1480. https://doi.org/10.1007/s00228-020-02920-1
22.    The use of the WHO-UMC system for standardised case causality assessment https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf
23.    Nagaraja BS, Ramesh KN, Dhar D, Mondal MS, Dey T, Saha S, Khan MA et al. HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern. J Public Health (Oxf). 2020;42:493-503. https://doi.org/10.1093/pubmed/fdaa074
24.    Kulkarni RK, Kinikar AA, Jadhav T. Adverse drug reaction profile of prophylactic hydroxychloroquine for COVID-19 among doctors. Medical Journal of Dr. DY Patil Vidyapeeth. 2020;13:204-207. https://www.mjdrdypv.org/article.asp?issn=2589-8302;year=2020;volume=13;issue=3;spage=204;epage=207;aulast=Kulkarni

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available